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Abstract
The past decade has seen the definition of key signalling pathways downstream of receptor
tyrosine kinases (RTKs) in terms of their components and the protein–protein interactions
that facilitate signal transduction. Given the strong evidence that links signalling by certain
families of RTKs to the progression of breast cancer, it is not surprising that the expression
profile of key downstream signalling intermediates in this disease has also come under
scrutiny, particularly because some exhibit transforming potential or amplify mitogenic
signalling pathways when they are overexpressed. Reflecting the diverse cellular processes
regulated by RTKs, it is now clear that altered expression of such signalling proteins in
breast cancer may influence not only cellular proliferation (eg Grb2) but also the invasive
properties of the cancer cells (eg EMS1/cortactin).
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kinase.
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Introduction
Ligand binding to RTKs induces receptor dimerization,
leading to activation of the intracellular kinase domain and
autophosphorylation of specific tyrosine residues. This
creates binding sites for phosphotyrosine binding
modules on signalling proteins, such as SH2 and phos-
photyrosine-binding domains [1]. SH2 domains are
modules of approximately 100 amino acids that recognize
phosphotyrosines within specific sequence contexts. This
is achieved through a bipartite binding site that consists of
a phosphotyrosine binding pocket and a pocket or groove
for specific residues that are carboxyl-terminal to the phos-
photyrosine. Phosphotyrosine-binding domains are con-
served sequences of 100–150 amino acids, a subset of
which recognize the consensus sequence NPXpY [1].
In addition to SH2 domains, many signalling proteins also
contain SH3 and/or pleckstrin homology domains. SH3
domains consist of 50–75 residues and bind proline-rich
motifs with the core sequence PXXP. Pleckstrin homology
domains bind to specific polyphosphoinositides and inosi-
tol polyphosphates, and thus regulate membrane associa-
tion and/or responses to the generation of specific
second messengers [1].
SH2 domain-containing proteins are divided into two classes
(Fig. 1a) [2]: class I proteins possess enzymatic activity and
include c-Src and phospholipase C (PLC)-g1; and class II
SH2 proteins, such as Grb2, do not have a known catalytic
activity and function as adaptor proteins, linking receptors or
cytoplasmic tyrosine kinases to downstream effectors.Breast Cancer Research    Vol 2 No 3 Kairouz and Daly
Overexpression of class I SH2 proteins may lead to signal
amplification through enhanced recruitment of the enzyme
to activated receptors. Class II SH2 proteins, however,
must bind to effector proteins with enzymatic activity in
order to generate a signalling cascade. In this case, the
effect of overexpression will depend on the ratio of cat-
alytic subunits to adaptors. If the adaptor is limiting, then
overexpression will result in increased complex formation
between adaptor and effector, as well as increased asso-
ciation of this complex with the receptor. Importantly, over-
expression of a particular signalling intermediate may
amplify signalling downstream of multiple growth factor
receptors if they couple to this pathway.
Altered expression of signalling intermediates
in human breast cancer
c-Src
The protooncogene c-src (Fig. 1a) is a nonreceptor tyrosine
kinase that is regulated by intramolecular interactions involv-
ing the SH2 and SH3 domains, the former binding phos-
phorylated Tyr530 at the carboxyl-terminus (for review [3]).
Evidence implicating a role for c-Src in breast cancer
emerged when two studies [4,5] demonstrated enhanced
c-Src kinase activity in breast tumours relative to that in
normal breast tissue. Furthermore, increased cytosolic tyro-
sine kinase activity, largely attributable to c-Src, correlated
with early systemic relapse in this disease [6,7]. Increases
in both the expression and specific activity of the enzyme in
breast cancers have been observed [5,7,8]. One mecha-
nism for activation of c-Src in breast cancer is through
SH2-domain-mediated association with the epidermal
growth factor (EGF) receptor and erbB2, which both
recruit this enzyme [9] and are commonly overexpressed in
this disease [10]. An alternative mechanism, however, is
through increased expression and/or activity of a Tyr530
phosphatase. Egan et al [11••] detected high levels of Src
kinase activity in four breast cancer cell lines compared
with in normal human foreskin fibroblasts and a normal
breast epithelial cell line. This correlated with reduced
phosphorylation of Tyr530 and increased membrane-asso-
ciated protein tyrosine phosphatase activity, which prefer-
entially dephosphorylated a synthetic Src family
carboxyl-terminal phosphopeptide. Interestingly, this activity
did not correlate with the expression or chromatographic
profile of several known protein tyrosine phosphatases.
Coupling of the EGF receptor to Src is considered in
more detail elsewhere in this thematic review [12], as is
evidence from transgenic models for a role of Src in
mammary tumourigenesis [13].
Phospholipase C-g g1
PLC-g1 (Fig. 1a) cleaves phosphatidylinositol (4,5) bis-
phosphate into the second messengers inositol-1,4,5-tris-
phosphate and diacylglycerol, leading to calcium
mobilization and activation of protein kinase C, respec-
tively. PLC-g1 tyrosine phosphorylation follows its interac-
tion with activated EGF and erbB2 receptors in vivo,
which stimulates its enzymatic activity [14].
Arteaga  et al [15] demonstrated by both immunohisto-
chemistry and immunoblotting that PLC-g1 was expressed
at higher levels in breast tumours relative to its expression
in normal tissue. Furthermore, PLC-g1 was tyrosine phos-
phorylated in the majority of the overexpressing tumours,
and this correlated with the presence of high levels of the
EGF receptor or erbB2. PLC-g1 expression was also
associated with oestrogen receptor (ER) negativity and a
higher histological grade.
Figure 1
Structure of signalling intermediates that exhibit aberrant expression in
human breast cancer. (a) Schematic representation of the structures
of c-Src and PLC-g1 (class I SH2 domain-containing proteins) and
Grb2 (a class II protein). PLC-g1 has two regions (designated PLC in
the figure) that constitute its catalytic domain, and the second
pleckstrin homology (PH) domain is interrupted by SH2 and SH3
modules. The different proteins and their domains are not drawn to
scale; for details refer to text. (b) Comparison of the molecular
architectures of Grb7 and Caenorhabditis elegans mig10. These two
proteins possess a homologous central region (termed the Grb–Mig or
GM domain), which contains a PH domain. Other than the presence of
proline-rich regions, however, the remainder of their structures are
dissimilar. (c) Schematic representation of EMS1/cortactin. The
filamentous actin-binding repeat region is separated from the carboxyl-
terminal SH3 module by a predicted helical domain followed by a
stretch of amino acids rich in serine, threonine and proline residues
(together designated HP in the figure).http://breast-cancer-research.com/content/2/3/197
The significance of PLC-g1 overexpression in breast
cancer is unclear, because studies investigating the role of
this enzyme in growth factor-stimulated proliferation have
yielded conflicting results [14]. It should be noted,
however, that PLC-g1 also regulates cytoskeletal reorgani-
zation and hence cell motility (eg via indirect effects on the
activity of actin-modifying proteins). Indeed, Chen et al
[16] demonstrated that activation of PLC-g1 was required
for EGF-mediated motility, but not for mitogenesis. Conse-
quently, overexpression of this enzyme may also influence
cellular invasion and/or metastasis.
Grb2
Grb2 is an adaptor protein that consists of a SH2 domain
flanked by two SH3 domains (Fig. 1a) [1,14]. Genetic and
biochemical evidence indicates that Grb2 serves to link
RTKs to the Ras pathway through binding of its SH3
domains to proline-rich regions in the GDP–GTP
exchange factor for ras, Sos.
In a study of Grb2 expression among breast cancer cell
lines [17], overexpression of Grb2 protein was observed
in MCF-7, MDA-MB-361 and -453 cells relative to normal
breast epithelial cells, and this was accompanied by a
small amplification of the GRB2 gene locus. Also,
increased Grb2 expression enhanced complex formation
with Sos. Recently, we have extended this analysis to
primary breast cancers (Yip et al, manuscript submitted),
and demonstrated that approximately 50% of those tested
exhibited a twofold or greater overexpression of GRB2
mRNA. Verbeek et al [18] found that Grb2 protein was
overexpressed in all primary breast cancers compared
with normal tissue, which suggests that a further upregula-
tion of Grb2 expression may also occur at the translational
level. Interestingly, in our study breast cancers exhibiting
low levels of the EGF receptor expressed significantly
higher GRB2 mRNA than high EGF receptor-expressing
breast cancers, suggesting selection for a mechanism that
amplifies signalling downstream from the receptor.
Although Grb2 does not have transforming potential when
overexpressed [19], early studies demonstrated that Grb2
overexpression could amplify activation of Ras or mitogen-
activated protein kinase (MAPK) in response to particular
growth factors [19–21]. More recently, these analyses
have been extended to mouse mammary tumourigenesis in
response to expression of polyomavirus middle T (PyV MT)
antigen, which couples to the Ras pathway via recruitment
of a Shc–Grb2–Sos complex. Mice that were transgenic
for PyV MT and heterozygous for GRB2 gene disruption
had a delayed onset of mammary tumours induced by PyV
MT relative to wild-type animals, indicating that the GRB2
gene dosage was limiting for tumourigenesis [22••]. It is
therefore likely that upregulation of Grb2 expression func-
tions in breast cancer progression to amplify signalling via
the Ras pathway downstream of particular tyrosine kinases.
The Grb7 family
The Grb7 family of adaptors consists of three proteins
(Grb7, Grb10 and Grb14), which display a conserved
structure (Fig. 1b; for review [23]). Recently, a novel
region was identified between the pleckstrin homology
and SH2 domains (the BPS domain), which, in the case of
Grb10 and Grb14, mediates binding to the activated
insulin receptor [24•,25•].
Stein et al [26] demonstrated that, due to the close prox-
imity of these genes on chromosome 17q, GRB7 is fre-
quently coamplified and coexpressed with ERBB2 in
breast cancer cell lines and tumours. Furthermore,
because Grb7 binds tightly to erbB2, this suggests that
amplification of a novel erbB receptor signalling pathway
occurs in a subset of breast cancers. We have recently
extended this analysis and demonstrated that Grb7 is also
recruited by erbB3 and erbB4 upon heregulin stimulation
of breast cancer cells [27]. Because Grb7 is also bound
by tyrosine phosphorylated Shc [26,27], this indicates
that Grb7 is a major component of the erbB receptor sig-
nalling cascade in breast cancer cells.
Grb10 and Grb14 are both recruited in vivo by the
insulin receptor [23,25•], although contrasting results
have been presented for the ability of Grb10 to coim-
munoprecipitate with the insulin-like growth factor (IGF)-I
receptor in vivo [23]. Grb10 is expressed by most breast
cancer cell lines [28], whereas GRB14 mRNA is differ-
entially expressed among a panel of such lines, expres-
sion correlating with ER positivity [29]. We have yet to
extend this analysis of Grb14 expression to primary
breast cancers.
We hypothesize that members of the Grb7 family have a
dual role in tyrosine kinase signalling. First, there is proba-
bly an adaptor function mediated by the amino-terminal
and GM regions, which may be related to regulation of
cell migration, because increased expression of a Grb7
variant correlates with the invasive and metastatic poten-
tial of oesophageal cancers, and downregulation of Grb7
in an oesophageal cancer cell line inhibits cell invasion
[30•]. Whether this is a reflection of their homology to
mig-10, which is required for long-range migration of
certain cell types during Caenorhabditis elegans devel-
opment [23], is unclear, and the effector molecules
involved are currently unknown. The second role is as
repressors of signalling by specific RTKs. For example,
overexpression of Grb14 reduces insulin-induced DNA
and glycogen synthesis [25•]. These results are compati-
ble with the Grb10/14 BPS–SH2 region binding the IGF-
I receptor/insulin receptor kinase domain and inhibiting
substrate recruitment and/or phosphorylation [24•,25•].
This repressor role is also supported by the recent identi-
fication of GRB10 as a candidate gene for Silver–Russell
syndrome [31].These two functions may reflect a need to coordinate cell
division with cell migration, and the net effect of overex-
pression of a Grb7 family protein may be determined by
the particular family member, the RTK system under study,
and the expression levels of receptor and adaptor. Conse-
quently, overexpression of Grb7 in breast cancer may lead
to a more invasive phenotype due to upregulation of the
adaptor (cell migration) function, whereas the loss of
Grb14 expression in ER-negative cell lines [29] can be
reconciled with the loss of a repressor of IGF signalling,
because the IGFs are important mitogens for breast
cancer cells (for review [32]). Clearly these issues need to
be addressed by further research at both a basic and
translational level.
EMS1/cortactin
EMS1 is the human homologue of the v-Src substrate cor-
tactin, and is a 80–85kDa multidomain protein that colo-
calizes with cortical actin [33] (Fig. 1c). Tyrosine
phosphorylation of EMS1/cortactin is increased by a
variety of stimuli, including growth factor receptor activa-
tion or integrin-mediated cell adhesion, and is tightly linked
to the activation of Src family kinases [34,35•]. Recombi-
nant cortactin binds and crosslinks actin filaments in vitro
via the repeat region, and this is inhibited by Src-mediated
tyrosine phosphorylation [34]. Overexpression of cortactin
increases cell motility in both fibroblasts [36] and
endothelial cells [35•], and this is dependent on the pres-
ence of the sites of tyrosine phosphorylation by Src [35•].
The gene encoding EMS1 localizes to chromosome
11q13, which is amplified in approximately 13% of breast
tumours, this correlating with ER positivity [37]. 11q13 is
a large amplicon of 2.5–5 Mb that contains several poten-
tial oncogenes in CCND1, INT-2/FGF3, HST-1/FGF4
and EMS1. Because the INT-2 and HST-1 genes are
rarely expressed in tumours with 11q13 amplification [37],
the candidate oncogenes are CCND1 and EMS1. A
recent study [38••] investigated the frequency of amplifica-
tion of EMS1 relative to other 11q13 markers in breast
cancer patients and the association of these events with
particular disease phenotypes. Analysis of approximately
1000 primary breast cancers revealed that EMS1 was
amplified in approximately 15% of the samples, and in 7%
of the patients this amplification was independent of
CCND1 or  INT-2. Interestingly, in common with CCND1,
EMS1 amplification was associated with increased risk of
relapse in lymph node-negative disease. Increased EMS1
gene copy number was associated with increased risk of
relapse and death in patients with ER-negative tumours,
but was without effect in ER-positive patients. In contrast,
CCND1 amplification was associated with poor prognosis
in the ER-positive, but not ER-negative subset. A further
study that examined EMS1 mRNA expression in a different
patient cohort also detected an association between
EMS1 overexpression and reduced disease-free survival
in ER-negative patients [39]. Consequently, not only are
CCND1 and EMS1 amplified independently, but they are
also associated with different disease phenotypes.
Considering the biological properties of EMS1, it is likely
that overexpression increases the invasive and/or metasta-
tic potential of the cancer cells. What are the possible
underlying mechanisms for the poor prognosis specifically
associated with EMS1-amplified, ER-negative tumours?
One possibility is enhanced tyrosine phosphorylation of
EMS1 due to activation of Src by the EGF receptor and
erbB2, the expression of which are inversely related to ER
status [10]. Tyrosine phosphorylation of EMS1/cortactin is
required for the increased motility of cells engineered to
overexpress this protein [35•]. However, serum or growth
factor treatment of EMS1-amplified cells leads to a mobil-
ity shift of EMS1/cortactin from 80 to 85kDa, which corre-
sponds to increased serine/threonine phosphorylation,
and a redistribution of the protein to cell–substratum
contact sites [40]. We have recently demonstrated [41•]
that the EGF-induced mobility shift is MAPK kinase-
dependent and identified the MAPKs as candidates for
phosphorylation of the EMS1 helical-proline-rich region.
Consequently, this represents a further mechanism
whereby EGF receptor signalling may modulate EMS1
function in ER-negative breast cancer cells.
Conclusion
Clearly some of the signalling proteins described in this
review are worthy of further investigation as potential prog-
nostic indicators, and the protein–protein interactions that
underlie their function provide attractive targets for thera-
peutic intervention. Further elucidation of the roles of
these proteins in breast tumourigenesis is likely to involve
manipulation via gene knockout and transgenic approaches,
as recently performed on Grb2 [22••]. However, we would
also like to highlight the synergy that can occur between
basic and translational research in this area, because our
recent clinical studies on EMS1 in breast cancer have pro-
vided interesting hypotheses regarding regulation of
EMS1 function, which are currently being addressed in
the laboratory.
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